Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic

Caroline A Steele, Daniel J Cuthbertson, Ian A MacFarlane, Mohsen Javadpour 1, Kumar S V Das 2, Catherine Gilkes 1, John P Wilding and Christina Daousi

Department of Obesity and Endocrinology, University of Liverpool, Liverpool, UK and Departments of 1Neurosurgery and 2Neuroradiology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK

(Correspondence should be addressed to C Daousi who is now at Obesity and Endocrinology Clinical Research Group, University Hospital Aintree, Clinical Sciences Centre, University of Liverpool, Lower Lane, Liverpool L9 7AL, UK; Email: cdaousi@liverpool.ac.uk)

Abstract

Objective: Obesity is highly prevalent among adults with acquired, structural hypothalamic damage. We aimed to determine hormonal and neuroanatomical variables associated with weight gain and obesity in patients following hypothalamic damage and to evaluate the impact of early instigation of weight loss measures to prevent or limit the severity of obesity in these patients.

Design: Retrospective study of 110 adults with hypothalamic tumours attending a specialist neuroendocrine clinic. BMI was calculated at diagnosis and at last follow-up clinic visit. Endocrine data, procedures, treatments and weight loss measures were recorded and all available brain imaging reviewed.

Results: At last follow-up, 82.7% of patients were overweight or heavier (BMI ≥ 25 kg/m²), 57.2% were obese (BMI ≥ 30 kg/m²) and 14.5% were morbidly obese (BMI ≥ 40 kg/m²). Multivariate analysis revealed that use of desmopressin (odds ratio (OR) = 3.5; P = 0.026), GH (OR = 2.7; P = 0.031) and thyroxine (OR = 3.0; P = 0.03) was associated with development of new or worsened obesity. Neuroimaging features were not associated with weight gain. Despite proactive treatments offered in clinic in recent years (counselling, dietetic and physical activity advice, and anti-obesity medications), patients have continued to gain weight.

Conclusions: Despite increased awareness, hypothalamic obesity is difficult to prevent and to treat. Improved understanding of the underlying pathophysiology and multicentre collaboration to examine efficacy of novel obesity interventions are warranted.

Introduction

The hypothalamus is known to be a vital regulator of weight equilibrium by balancing energy intake with energy expenditure and body fat stores. When the hypothalamus is damaged, a syndrome of intractable weight gain can ensue termed ‘hypothalamic obesity’ (HO), which has received increased attention in recent years (1). The most common causes of acquired hypothalamic damage are space-occupying lesions, such as craniopharyngiomas and pituitary macroadenomas, with suprasellar extension and invasion of the hypothalamic nuclei. Hypothalamic damage can be caused by the tumour itself, or by its subsequent treatment with surgery or radiotherapy (2).

We had previously shown that obesity is highly prevalent among adult patients with acquired, structural hypothalamic damage and awareness had been raised of this significant complication among clinicians (1). HO is associated with a number of adverse health consequences leading to increased morbidity and mortality, i.e. cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), sleep-disordered breathing, non-alcoholic fatty liver disease (NAFLD), reduction in functional capacity and impaired quality of life. With regard to cardiovascular risk factors, these are highly prevalent and often inadequately treated in adult patients with hypothalamic–pituitary disease (3). Aggressive treatment of these factors is essential to reduce mortality and morbidity from CVD in these patients (4).

Effective treatments for HO have not yet been developed or evaluated. Following the publication of our initial findings in 2005, we adopted a more proactive approach to the management of these patients at risk of severe HO and its complications, aiming to limit the severity of weight gain through the early provision of dietary and behavioural modification, counselling, encouragement of regular physical activity, use of anti-obesity medications and referral to multidisciplinary weight management services.
This retrospective study had the following aims: i) to ascertain the prevalence of obesity in one of the largest cohorts of adult patients who have sustained hypothalamic damage and have been followed up in a single centre in the UK. ii) to help determine hormonal and neuroanatomical variables associated with the development of new or worsened obesity following hypothalamic damage and iii) to evaluate the impact of early instigation of weight loss measures in an attempt to help prevent the development of or limit the severity of HO.

Materials and methods

Patients

A retrospective study was conducted on 110 adult patients with tumours involving the hypothalamic–pituitary region. All patients were attending a regional joint surgical and neuroendocrine clinic at the Walton Centre for Neurology and Neurosurgery in Liverpool, UK. Permission from the Institution’s Audit Department was obtained and data were retrieved from the medical case notes and electronic records. All patients had undergone treatment for hypothalamic tumours, or adjacent tumours directly compressing or invading the hypothalamus. Fifty-three patients (48.2%) had pituitary macroadenomas and hypothalamic invasion, 38 patients (34.5%) had craniopharyngiomas and 19 patients (17.3%) had other hypothalamic lesions (hypothalamic hamartomas, gliomas and histiocytosis X). The data described here represent clinical data from 2010 to early 2011. Treatment modalities including neurosurgical procedure(s) (transsphenoidal surgery or craniotomy), need for insertion of a ventricular drainage device and administration of conventional fractionated radiotherapy were recorded.

Assessments

Patients’ height and weight at the time of diagnosis of their tumour were recorded where available. BMI (kg/m²) was calculated at diagnosis and at the last follow-up clinic visit. Changes in BMI were determined to identify the development of new or worsened obesity (defined as a BMI ≥ 30 kg/m² at last follow-up clinic visit, which had also increased by at least 2 kg/m² since the diagnosis of the tumour) (1). The glucagon stimulation test was used to assess ACTH and GH reserve. All patients with an inadequate cortisol response to glucagon underwent standard dose (250 μg) short synaッチchen testing to confirm cortisol deficiency. Basal morning levels of TSH, free thyroxine, free triiodothyronine, prolactin, oestradiol, testosterone, cortisol and insulin-like growth factor 1 were also used to assess endocrine status as described previously (1). All available pre- and post-operative computed tomography (CT) and magnetic resonance imaging (MRI) scans for each patient were reviewed and scored by the same radiologist who was blind to the clinical data. The following anatomic features were recorded pre- and postoperatively: primary site of tumour; maximum extent (mm) of the tumour from the midline (to the right and left) on coronal views; presence of suprasellar extension of pituitary tumours; encroachment of pituitary tumours on the optic chiasm; invasion or compression by extrahypothalamic tumours of adjacent hypothalamic tissue; distortion of the third ventricle on coronal images at the level of the infundibulum; any abnormalities of the floor of the third ventricle (partial or complete deficiency of the floor of the third ventricle) or breach of the tuber cinereum by the tumour and infiltration by the tumour of other brain areas, including the thalamus and temporal lobes. An MRI-based score of hypothalamic damage was produced for each patient based on the grading system previously described by Sainte-Rose.

Statistical analysis

The Wilcoxon signed-rank test was used to compare longitudinal changes in BMI in the 77 patients in whom serial data were available. Multiple logistic regression analysis was used to identify features associated with weight gain. Variables that differed significantly in the univariate analysis for patients with new or worsened obesity at latest follow-up were entered into the model. Statistical significance was defined as \( P < 0.05 \) (two-tailed). All analyses were performed using SPSS, version 18.0.

Results

Prevalence of obesity

The entire cohort consists of 110 patients, with a median age of 55.5 years and a mean (± s.d.) BMI of 33.7 (± 7.5, range 19–60) kg/m². At last follow-up, 91 patients (82.7%) were overweight or heavier (BMI ≥ 25 kg/m²), 63 (57.2%) were obese (BMI ≥ 30 kg/m²) and 37 (33.6%) had a BMI ≥ 35 kg/m²: 16 (14.5%) patients were morbidly obese (BMI ≥ 40 kg/m²). In comparison, in the general population of a similar age (aged 55–64 years), mean BMI is 28.2 kg/m², 73.5% are overweight or heavier (BMI ≥ 25 kg/m²) and 31% are obese (BMI ≥ 30 kg/m²) (Health Survey for England 2007, The NHS Information Centre) (5). The prevalence of obesity in our population of patients with hypothalamic damage is nearly double that seen in the general background population. At their last clinic visit, 103/110 (94%) patients were receiving replacement therapy with one or more pituitary hormone replacements, including 30 (27%) who were receiving desmopressin for cranial diabetes insipidus.
Treatments for obesity
Seventeen patients from the entire cohort have received treatment with orlistat in recent years and four patients had received multiple weight loss medications (orlistat, sibutramine and rimonabant, the latter two before their withdrawal from the market due to safety concerns). Six patients at their last clinic follow-up were attending a hospital-based multi-professional weight management clinic, all of whom were seen regularly by a dietician and a physician with a special interest in weight management. None of the patients in our cohort had undergone bariatric surgery.

Longitudinal changes in weight and BMI
At the time of diagnosis and treatment of their tumour, height and weight measurements were available for 77 out of the 110 patients. Their mean (± s.d.) age at last clinic assessment was 44 ± 16.5 years. There was a highly significant increase in median BMI, from 28.1 kg/m^2 at baseline (IQR, 24.3–32.4 kg/m^2) to 32 kg/m^2 (IQR, 27.7–38.38 kg/m^2) at the last follow-up (P < 0.0001), a median of 9 years after diagnosis of their tumour. Weight gain was fastest within the first year after diagnosis of their tumour, with an increase in mean BMI to 30.4 kg/m^2 (P < 0.0001); the rate of weight gain subsequently declined but did not plateau.

Variables associated with obesity and weight gain since diagnosis
Patients with new or worsened obesity at last clinic follow-up were more likely to be receiving GH replacement therapy (P = 0.007), thyroxine (P = 0.008) or desmopressin (P = 0.02). Multivariate analysis revealed that use of desmopressin (odds ratio (OR) = 3.5; 95% CI: 1.2 to 10.8; P = 0.026), GH (OR = 2.7; 95% CI: 1.1 to 6.9; P = 0.031) and thyroxine (OR = 3.0; 95% CI: 1.1 to 8.0; P = 0.03) was associated with the development of new or worsened obesity. A number of neuroradiological features examined on preoperative CT/MRIs and post-operative neuroimaging and the original histological diagnosis were not associated with weight gain and patients’ obesity status at last clinic assessment (Table 1). The degree of hypothalamic damage as assessed by the MRI-based score using the Sainte-Rose grading system (grade 1 and grade 2 hypothalamic damage) did not impact on the risk of development of new or worsened obesity. Similarly, treatment modalities with a greater theoretical likelihood of causing hypothalamic damage, such as craniotomy or radiotherapy, were not associated with increased weight gain following diagnosis.

Table 1 Characteristics of the patients with serial data (n = 77) according to obesity status.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>New or worsened obesity (n = 42)</th>
<th>No weight gain (n = 35)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current age (years)</td>
<td>55.7 ± 13.1</td>
<td>54.2 ± 17.7</td>
<td>0.9</td>
</tr>
<tr>
<td>Age at diagnosis (years)</td>
<td>43.4 ± 15.7</td>
<td>44.5 ± 17.7</td>
<td>0.4</td>
</tr>
<tr>
<td>Male sex</td>
<td>22 (52.4)</td>
<td>21 (60)</td>
<td>0.4</td>
</tr>
<tr>
<td>Years of follow-up</td>
<td>10.8 ± 6.8</td>
<td>8.5 ± 5.9</td>
<td>0.6</td>
</tr>
<tr>
<td>Baseline BMI (kg/m^2)</td>
<td>30.9 ± 6.8</td>
<td>26.2 ± 4.8</td>
<td>0.001</td>
</tr>
<tr>
<td>Current BMI (kg/m^2)</td>
<td>38.6 ± 7.2</td>
<td>27.4 ± 3.6</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Transsphenoidal surgery</td>
<td>18 (43)</td>
<td>22 (63)</td>
<td>0.2</td>
</tr>
<tr>
<td>Craniotomy</td>
<td>21 (50)</td>
<td>10 (29)</td>
<td>0.07</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>26 (62)</td>
<td>18 (51)</td>
<td>0.4</td>
</tr>
<tr>
<td>Ventriculoperitoneal shunt</td>
<td>7 (17)</td>
<td>4 (11)</td>
<td>0.5</td>
</tr>
<tr>
<td>Hydrocortisone replacement</td>
<td>34 (81)</td>
<td>23 (66)</td>
<td>0.2</td>
</tr>
<tr>
<td>Hydrocortisone dose (mg)</td>
<td>22.3 ± 5.3</td>
<td>25.7 ± 6.2</td>
<td>0.04</td>
</tr>
<tr>
<td>GH replacement</td>
<td>29 (69)</td>
<td>14 (40)</td>
<td>0.007</td>
</tr>
<tr>
<td>Thyroxine replacement</td>
<td>35 (83)</td>
<td>18 (51)</td>
<td>0.008</td>
</tr>
<tr>
<td>Sex steroids</td>
<td>27 (64)</td>
<td>16 (46)</td>
<td>0.9</td>
</tr>
<tr>
<td>Desmopressin</td>
<td>15 (36)</td>
<td>6 (17)</td>
<td>0.02</td>
</tr>
<tr>
<td>Invasion of thalamus on MRI</td>
<td>1 (2)</td>
<td>2 (6)</td>
<td>0.5</td>
</tr>
<tr>
<td>Invasion of temporal lobe on MRI</td>
<td>6 (14)</td>
<td>4 (11)</td>
<td>0.5</td>
</tr>
<tr>
<td>Abnormalities of third ventricle</td>
<td>15 (36)</td>
<td>14 (40)</td>
<td>0.9</td>
</tr>
</tbody>
</table>

MRI, magnetic resonance imaging.

Patients diagnosed with hypothalamic tumours between 2005 and 2011
Since the publication of our findings in 2005 of high prevalence of obesity among patients with acquired hypothalamic damage, 35 new patients with hypothalamic tumours have been diagnosed and treated at our centre. The mean (± s.d.) age of these 35 patients at diagnosis was 50.9 ± 16.6 years and 23 (66%) were men. After a median period of follow-up of 3 years, there has been an increase in median BMI from 29.9 kg/m^2 (IQR, 26.5–33.4 kg/m^2) at baseline to 31.7 kg/m^2 (IQR, 27.8–38.8 kg/m^2) at last clinic follow-up (P < 0.001) (Fig. 1). Despite the increase in awareness...
and proactive treatments offered in our clinic since the dissemination of our findings in 2005, newly diagnosed patients have continued to gain weight. All these patients were adequately hormonally replaced where necessary and all had received counseling about their weight, dietetic advice and encouragement for regular physical activity if other co-morbidities permitted. Five of the patients had been treated with anti-obesity medications (four treated with orlistat and one with orlistat followed by sibutramine) and one patient was attending a hospital-based multi-professional weight management clinic.

Discussion

This is the largest ever study examining BMI trends and weight gain patterns in adult patients with acquired structural hypothalamic damage. Our current findings of a continuing increase in the prevalence and severity of obesity in these patients reflect the difficulty in both preventing and treating obesity secondary to hypothalamic damage. These body weight changes occurred despite increased awareness of the problem in our clinic population (1) and early instigation of measures such as dietary advice, professional dietetic input, recommendation of regular physical activity and, where considered clinically appropriate, drug therapy to support weight loss.

The increased prevalence of cardiovascular risk factors and the metabolic syndrome, well documented in patients with hypothalamic–pituitary disease (3) and craniopharyngioma (6, 7), are also particularly common in those with hypothalamic damage that has occurred at a relatively young age (8) despite adequate pituitary hormone replacement (8). Obesity is associated with numerous co-morbidities such as CVD, T2DM, hypertension, NAFLD, certain cancers and sleep apnoea. In fact, obesity is an independent risk factor for CVD (9). These observations combined highlight the importance of the high prevalence of obesity in a population with an already increased CVD background.

Our current data confirm our previous findings from a smaller cohort of patients (1) that pre- and post-operative MRI in adult patients with hypothalamic damage cannot predict patients at high risk of post-operative weight gain. Other groups have described a correlation between MRI findings and the risk of HO in children with craniopharyngiomas (10, 11). The extent of involvement of the hypothalamus on preoperative MRI has been used by others to help guide treatment in terms of extent of resection of craniopharyngioma (12), where preservation of the hypothalamus is advocated rather than complete (total) surgical resection, in those without hypothalamic involvement. A recent paper by Van Gompel et al. (13) of 28 adult patients with craniopharyngioma undergoing surgery found that a worse preoperative MRI score, using a scale described by Sainte-Rose et al. (14), was associated with an increased risk of post-operative weight gain. However, they limited the follow-up to a maximum of 2 years and no patients in their study were treated with GH, and it remains unclear how many of their patients had symptomatic severe GH deficiency that would have warranted replacement (13). These factors and their limitation to patients with craniopharyngioma only may explain the differences from our findings.

Multivariate analysis revealed that GH, levothyroxine and desmopressin replacement were associated with development of new or worsened obesity and the requirement for multiple endocrine replacements may reflect the extent of hypothalamic damage, such as bilateral damage to the paraventricular and supraoptic nuclei in patients with permanent central diabetes insipidus. The paraventricular nucleus, apart from its role in vasopressin release, is also an important part of the neuroendocrine circuitry that controls energy balance. These circuits would be unlikely to remain completely intact following a hypothalamic insult that also leads to cranial diabetes insipidus.

There are multiple different theories as to the pathophysiology underlying weight gain and obesity in those with acquired structural hypothalamic damage. A few of the proposed pathophysiological mechanisms are: hyperphagia and increased energy intake; hyperinsulinism due to autonomic nervous system dysregulation, leptin resistance, reduced physical activity and reduced basal metabolic rate; melatonin dysregulation and enhanced 11-β hydroxysteroid dehydrogenase-1 activity (15, 16, 17, 18). It seems likely that, as the hypothalamus is responsible for both integrating and initiating multiple pathways influencing body weight, any or several of these mechanisms may be responsible and that this may vary between individual patients (15, 19, 20).
Treatment of simple obesity is extremely challenging; however, HO is even more refractory to conventional therapeutic interventions. Given the multiple underlying pathophysiological pathways, which may become disturbed and contribute towards HO, it is not surprising that no single effective treatment has been developed and successfully applied. A variety of pharmacological approaches have been tried over the years, targeting a number of different putative pathophysiological mechanisms underlying HO. One such approach aimed at lowering insulin levels that have previously been demonstrated to be elevated in children with HO (21, 22). An open-label and a double-blind, placebo-controlled trial with the somatostatin agonist octreotide in children with HO has demonstrated weight loss and weight stabilisation along with reductions in insulin levels (21, 22). There is limited evidence for the use of sibutramine (23, 24), dextroamphetamine (25, 26), metformin (27), GLP-1 receptor agonists (28), supraphysiological doses of T3 (29) and melatonin (30) as treatments in HO in both children and adults. No studies of orlistat in the HO population exist; however, its use has been mentioned in only a few case reports. We have used orlistat in a small number of our patients (n=17), with variable results. A small number of reports have been published describing the use of bariatric surgery in patients with HO showing significant weight loss and weight loss maintenance (31, 32, 33, 34).

Based on our collective experience from our clinic population of adults with hypothalamic tumours, we would recommend regular weight measurements to be undertaken at every clinic visit. After ensuring adequate replacement (without over-replacement) of all pituitary hormone deficits, it is important to consider dietary and exercise advice as first-line measures and counselling of the patient regarding the increased risk of weight gain especially within the first year following treatment of their hypothalamic tumour. Lifestyle programmes alone are unlikely to be sufficient and there are no studies that conclusively demonstrate the effectiveness of physical activity in patients with HO. Drug therapy is often needed in addition, and as in simple obesity, it is of variable success. Referral to a multi-disciplinary weight management service (where available) should also be considered, but patients should be warned that their weight gain may be difficult to treat despite in some cases no evidence of inappropriate diet or sedentary lifestyle. It is important to emphasise to the patients, however, that while their weight gain and obesity may be more refractory to the usual diet and exercise advice, there are currently limited treatment options available and therefore it is even more important to ensure that these aspects are addressed adequately. Stabilisation of weight, after years of incessant weight gain, is as much of an achievement as weight loss in these patients. Questioning regarding complications of obesity, such as development of T2DM, NAFLD or sleep apnoea, with referral for further specialist assessment, is also important.

To further investigate the underlying pathophysiology involved in weight gain following hypothalamic damage, non-invasive modalities such as functional neuroimaging (positron emission tomography and functional MRI) may provide useful insights, as it has in those with simple obesity. Functional neuroimaging has helped to identify neuroanatomical correlates of hunger, satiety and feeding and has demonstrated how the brain is affected under different experimental conditions (35, 36, 37, 38), after presentation of food images (with differences between high-calorie, low-calorie and neutral picture stimuli) (37, 39) and has demonstrated differences between obese and lean individuals (36, 37, 40). Functional neuroimaging studies in patients with HO may help shed light on the underlying pathophysiology.

Engagement and compliance with the weight management treatments offered in our study were excellent and all participants were highly motivated and keen to avoid further weight gain or to achieve clinically meaningful weight loss. Caution should be exercised when interpreting the response to these weight loss interventions as the number of patients studied was small. As HO is a relatively rare condition with little awareness from the medical and surgical communities, multicentre collaboration involving specialist centres for further research, including perhaps multi-drug trials and ideally randomised trials of intensive lifestyle interventions vs routine care, would be beneficial to patients and clinicians.

Declaration of interest

C Daousi, D J Cuthbertson and J P Wilding have received research grants from Merck Sharp & Dohme (MSD), Eli Lilly and the NovoNordisk UK Research Foundation. J P Wilding has received consulting and speaker fees from MSD, NovoNordisk, Astra Zeneca and Eli Lilly. C Daousi, I A MacFarlane and D J Cuthbertson have received research grant support from Otsuka, Lilly, Ipsen and Pfizer. C A Steele, K S V Das, C Gilkes and M Javadpour have nothing to disclose.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References


10 Roth CL, Gebhardt U & Muller HL. Appetite-regulating hormone changes in hypothalamic craniopharyngioma. *Obesity* 2011 19 36–42. (doi:10.1038/oby.2010.80)


Received 9 September 2012
Revised version received 16 December 2012
Accepted 3 January 2013